retatrutide drug trial Phase III study demonstrates 30% weight loss Lilly's triple agonist, retatrutide, delivered

2023;102(9):e33109

GLP-1 receptor agonists like Ozempic may pose risks for patients with ulcerative colitis

GLP-1 Diet for Women: A Beginners Guide to Understanding GLP-1 and a 5-Step Plan to Naturally Activate It with Recipes & Meal Plans

GLP1s while breastfeeding depends on several factors, including dosage form, mother's personal choice, and overall risk-benefit balance.

For the first time ever, Medicare will cover medications for weight loss, through a new program launched this month

Its multifaceted mechanism mirrors the bodys natural hormonal orchestration, providing researchers with a powerful tool for studying amplified metabolic effects